GRAIL (GRAL) Q2 FY26 earnings call

GRAIL delivered strong Q2 FY26 results, driven by significant Galleri test volume and revenue growth, supported by a strategic financing and expanded sales force. The company is advancing towards anticipated FDA approval for Galleri in early 2027, with an advisory committee expected in the fall, despite competitive noise from unproven MCED tests. Management remains confident in its robust clinical data and differentiated methylation technology.